Welcome back! So completes THE most boring summer in investing history. Well maybe not quite, but pretty damn close. It is astounding that markets have been so complacent in front of the fall investing season with a litany of worries globally, including our own US presidential election less than 90 days away. I myself am much less anxious about that result since I swore off watching the nightly....More>>>
Small cap RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) is focused on regenerative medicine – a game-changing area of medicine with the potential to fully heal damaged tissues and organs. According to Wikipedia, the term wasfirst used in a 1992 article on hospital administration by Leland Kaiser anddeals with the “process of replacing, engineering or regenerating human cells, tissues....More>>>
Shares of CRISPR biopharma Editas Medicine (NASDAQ:EDIT) jumped nearly 33% higher today, after the U.S. Patent and Trademark Office (USPTO) announced that the Broad Institute would keep its claims to valuable patents on clustered regularly interspaced short palindromic repeats, or CRISPRs, which make up the foundation of the company’s gene-editing technology platform.....More>>>
This week, Botox maker Allergan plc (NYSE:AGN) shelled out $2.5 billion for body-sculpting outfit Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). The pairing is a nice opportunity for both organizations to cross-sell to one another’s customers. Allergan’s Botox customers seeking a more youthful face will also likely want the better body Zeltiq Aesthetics provides, and Zeltiq Aesthetics’....More>>>
After posting Impressive earnings, TWLO stock is a high risk/reward bet as risks associated with Twilio Inc still persist.
San Francisco, California-based cloud communications platform provider Twilio Inc(NYSE:TWLO)reported its Q4 2016 and FY 2016 (ended December 31, 2016)financial results on Feb 7th. Twilio broke even on a non-GAAP basis on revenue of $82M for the fourth quarter.....More>>>